The SYNEBIO project, titled "High-throughput combinatory drugs testing on in vitro 3D cells model platform," aims to advance drug testing methodologies by leveraging innovative microfluidic systems. These systems are designed to test drug combinations on cells embedded in 3D hydrogel environments, which better mimic the in vivo conditions of human tissues compared to traditional 2D cell cultures. This approach addresses the critical need for more accurate preclinical drug testing models, which are essential for predicting the efficacy and safety of new treatments in humans.
Traditional 2D cell cultures have been the cornerstone of preclinical drug testing; however, they fall short in replicating the complex 3D architecture of human tissues, leading to discrepancies in drug responses observed in laboratory settings versus clinical trials. The SYNEBIO project seeks to bridge this gap by providing a high-throughput, scalable platform that offers a more realistic tissue environment. This advancement is expected to streamline the drug development process, reduce costs, and ultimately lead to more effective therapies.
The impact of the SYNEBIO project spans scientific, medical, and economic domains:
1. Enhanced Drug Development Efficiency: The platform's ability to perform high-throughput testing of drug combinations in a 3D environment is poised to accelerate the drug development process. By providing more reliable preclinical data, the project aims to reduce the time and resources needed to bring new drugs to market.
2. Improved Drug Efficacy and Safety: Testing drugs in a 3D environment that closely simulates human tissues can lead to better predictions of how drugs will perform in clinical settings. This can minimize the risk of adverse effects and improve the overall efficacy of treatments, particularly for complex diseases such as cancer.
3. Advancements in Cancer Treatment: Initially focused on lung cancer, the platform has the potential to be adapted for other types of cancer and diseases. This adaptability supports the development of personalized medicine approaches, where treatments are tailored to the specific needs of individual patients based on the detailed understanding of drug interactions within a 3D cellular context.
4. Economic and Industrial Benefits: The project supports the creation of a spin-out company, fostering innovation and economic growth. Collaborations with pharmaceutical companies like Sanofi and engagement with potential investors highlight the strong industrial interest and potential for significant commercial impact. The project has already secured additional funding from various sources, further underscoring its potential.
